• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TauRx Therapeutics, Toronto Memory Program announce phase III trials

TauRx Therapeutics, Toronto Memory Program announce phase III trials

June 12, 2013
CenterWatch Staff

Neurodegenerative disease specialist TauRx Therapeutics and Toronto Memory Program have joined in the Canadian launch of the phase III clinical trials of TauRx Therapeutics' LMTX, the company's investigational treatment aimed at slowing or halting the progression of mild to moderate Alzheimer's disease.

"The approval given by Health Canada to TauRx to initiate these phase III clinical studies marks an important step forward in our quest to find a disease-modifying agent that can help slow or halt the progression of Alzheimer's disease for Canadians and others," said Claude Wischik, TauRx Therapeutics executive chairman and co-founder.

Wischik said, "Unlike cancer where we often talk about 'survivors,' in Alzheimer's there are no 'survivors.' Alzheimer's is a terminal illness, so a medicine that can keep people functioning and at home is essential."

The four drugs currently approved for the treatment of Alzheimer's target the symptoms rather than the causes. TauRx's clinical trials for Alzheimer's and for behavioral variant Frontotemporal Dementia, a rare neurodegenerative disease caused by a similar form of pathology, are the first phase III trials of a Tau Aggregation Inhibitor (TAI), which targets and dissolves 'tau tangles' in the brain, and directly linked to the development of the disease.

If successful, LMTX will be the first tau-based treatment approach for Alzheimer's.

Canada plays an important role in TauRx phase III study that will involve over 1,700 patients in more than 20 countries. These studies culminate three decades of research by Wischik and colleagues at TauRx, a spin-out from the University of Aberdeen, Scotland, established 11 years ago.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing